CGTX

Business Context and Reporting Period

Cognition Therapeutics, Inc. (CGTX) is a clinical-stage biopharmaceutical company developing small molecule therapeutics for age-related degenerative diseases, primarily focusing on its lead candidate, zervimesine (CT1812), for Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB). The company operates as a single segment and relies heavily on non-dilutive grants from the National Institute on Aging (NIA) to fund its clinical trials. This 10-K covers the fiscal year ended December 31, 2024.

Key Financial Metrics

Liquidity and Capital Resources: As of December 31, 2024, the company held $25.0 million in cash and cash equivalents. Management has raised approximately $138.0 million in net proceeds from equity sales and grants since inception. The company has an "at-the-market" (ATM) facility with $21.9 million remaining and an equity line with Lincoln Park Capital with $34.8 million available, though no shares were sold under the Lincoln Park facility in 2024.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by $8.2 million (32%) year-over-year, driven by a $5.3 million decrease in grant income and a $3.2 million increase in operating expenses.
• Operating Expenses: Research and development (R&D) expenses rose by $4.5 million to $41.7 million, primarily due to increased Phase 2 clinical trial activities ($6.5 million) and personnel costs ($1.6 million). General and administrative expenses decreased by $1.2 million to $12.3 million, largely due to lower equity-based compensation.
• Grant Income Decline: Grant income decreased to $19.5 million from $24.8 million, correlating with a decrease in eligible reimbursable costs incurred during the year.
• Strategic Pivot: In January 2025, the company voluntarily concluded the MAGNIFY Phase 2 study for geographic atrophy (dry AMD) to focus resources on AD and DLB programs. This decision was not due to safety concerns but to preserve capital.

Guidance, Outlook, and Risks

Going Concern: The company has stated there is substantial doubt about its ability to continue as a going concern for the twelve months following the issuance of the report. Management believes current cash, cash equivalents, and grant income will fund operations only into the fourth quarter of 2025, assuming no usage of remaining ATM or equity line facilities.

Clinical Outlook:

• Alzheimer's Disease: The Phase 2 SHINE study reported top-line results in 2024 showing cognitive benefits in a biomarker-defined population. The Phase 2 START study (MCI/early AD) is ongoing.
• Dementia with Lewy Bodies: The Phase 2 SHIMMER study concluded in 2024 with top-line results presented in early 2025 showing benefits across behavioral, functional, cognitive, and motor scales.

Key Risks:

• Capital Needs: The company requires substantial additional capital to fund operations and development. Failure to raise capital could force curtailment of operations.
• Nasdaq Compliance: The company received a deficiency letter regarding the $1.00 minimum bid price requirement. It transferred to the Nasdaq Capital Market in March 2025 and has an additional 180-day grace period to regain compliance.
• Grant Dependency: Operations rely on NIA grants. Changes in government funding policies or audit findings could materially impact financial condition.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $25.0 million cash balance against the projected burn rate to confirm the Q4 2025 liquidity timeline.
• Nasdaq Status: Monitor the stock price to ensure compliance with the $1.00 minimum bid price requirement by September 8, 2025, to avoid delisting.
• Grant Funding: Assess the risk of reduced NIA funding under changing political administrations and the potential impact on the $50 million in obligated future grant funds.
• Clinical Data: Review the full data release from the SHINE and SHIMMER trials to validate the efficacy signals reported in top-line results.
• Capital Raising: Evaluate the terms and likelihood of success for future equity offerings given the current stock price volatility and market conditions.